Compare DexCom, Inc. (DXCM) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? DexCom, Inc. trades at $91.14 (market cap $34.26B), while Vanguard Total Stock Market Index Fund ETF trades at $384.2. Which is the better fit depends on your goals.
| DXCM | VTI | |
|---|---|---|
Market Cap | $34.26B | — |
Sector | Health | — |
52-Week High | $90.80 | $381.83 |
52-Week Low | $54.84 | $311.68 |
Enterprise Value | $33.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
VTI trades at $381.83, up 0.05% with a bullish technical signal from moving averages and strong institutional inflows. The ETF's 0.03% expense ratio and over 3,500 holdings provide broad U.S. equity exposure. Recent dividend of $1.04 was declared for June 2026.
Outlook remains positive due to low-cost diversification and steady institutional demand. Risks include market volatility and concentration in large-cap tech. Long-term growth potential is supported by historical performance but requires monitoring of economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
